Cyanine7.5 hydrazide
| Cat. # | Quantity | Price | Lead time | Buy this product |
|---|---|---|---|---|
| 16070 | 1 mg | $110.00 | in stock | |
| 26070 | 5 mg | $210.00 | in stock | |
| 46070 | 25 mg |
$410.00
|
in stock | |
| 56070 | 50 mg |
$695.00
|
in stock | |
| 66070 | 100 mg |
$1190.00
|
in stock |
A carbonyl-reactive hydrazide derivative of Cyanine7.5 near infrared (NIR) fluorophore. This dye has similar spectral properties with ICG (indocyanine green), but has a higher quantum yield of fluorescence. Hence, this fluorophore is ideal for in vivo imaging.
This is a carbonyl-reactive dye which is particularly useful for the labeling of antibodies after periodate oxidation. It also labels other carbonyl compounds (aldehydes and ketones), for example, many saccharides.
Cyanine7.5 absorbance and emission spectra
Customers also purchased with this product
Sulfo-Cyanine7 NHS ester
Sulfo-Cyanine7 NHS ester is a water soluble, near infrared, amine-reactive dye.Cyanine7.5 amine
Near infrared dye Cyanine7.5 with free amino group.BDP TR hydrazide
BDP TR hydrazide for the labeling of carbonyl compounds with BDP TR, a borondipyrromethene matching ROX/Texas Red channel.General properties
| Appearance: | green powder |
| Mass spec M+ increment: | 644.4 |
| Molecular weight: | 735.82 |
| Molecular formula: | C45H52Cl2N4O |
| Solubility: | moderate solubility in water, good in polar organic solvents (DMF, DMSO, alcohols) |
| Quality control: | NMR 1H, HPLC-MS (95%) |
| Storage conditions: | Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. Avoid prolonged exposure to light. Desiccate. |
| MSDS: | Download |
| Product specifications |
Spectral properties
| Excitation maximum, nm: | 788 |
| ε, L⋅mol−1⋅cm−1: | 223000 |
| Emission maximum, nm: | 808 |
Product citations
- Liu, S.; Dozois, M.D.; Chang, C.N.; Ahmad, A.; Ng, D.L.T.; Hileeto, D.; Liang, H.; Reyad, M.-M.; Boyd, S.; Jones, L.W.; Gu, F.X. Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage. Molecular Pharmaceutics, 2016, 13(9), 2897–2905. doi: 10.1021/acs.molpharmaceut.6b00445
Cy® is a trademark of GE Healthcare.
The count of items is incorrect.
Your cart is empty
$ 
